A carregar...
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A...
Na minha lista:
| Publicado no: | Clin Pharmacol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5720043/ https://ncbi.nlm.nih.gov/pubmed/29270033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S130178 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|